Endoxan® clinical trials

PembrolizuMab beyond RECIST progression and oral metroNOmic cyclophosphamide in meTAstatic UROthelial cancer: a single-arm, monocentre, phase 2 trial: minotaURO study

This study is looking at a new way to treat bladder cancer that has spread. It combines immunotherapy (pembrolizumab) with a cancer drug (cyclophosphamide) to see if it can stop the cancer from getting worse for longer. It's for adults and focuses on how well the treatment works.